Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on rare muscle disorders

NCT ID NCT07391605

Recruiting now Disease control Sponsor: Cartesian Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a personalized cell therapy called Descartes-08 for people with dermatomyositis or antisynthetase syndrome, two rare autoimmune diseases that cause muscle weakness and inflammation. The therapy uses a patient's own immune cells, modified to target and reduce harmful immune activity. About 60 participants will receive either Descartes-08 or a placebo to see if it leads to major improvement in muscle function and disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Descartes-08 (a personalized cell therapy made from the patient's own immune cells, engineered to target and destroy certain immune cells that drive the disease)
What this could lead to
If successful, this could point toward a new treatment option for people with these rare autoimmune muscle diseases, potentially reducing symptoms and improving quality of life.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The therapy is complex and carries risks like infusion reactions or infections. It may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTISYNTHETASE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antisynthetase syndrome dermatomyositis myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTISYNTHETASE SYNDROME

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • T12

    RECRUITING

    Orange, California, 92868, United States

  • T13

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

  • T22

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • T23

    RECRUITING

    Austin, Texas, 78759, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.